Oncology
9. Zaakouk M, Quinn C, Provenzano E, Boyd C, Callagy G, Elsheikh S, et al. Concordance of HER2-low scoring in breast carcinoma among expert pathologists in the United Kingdom and the republic of Ireland – on behalf of the UK national coordinating committee for breast pathology. Breast. 2023 Aug 1;70:82–91.
10. Curigliano G, Hu X, Dent RA, Yonemori K, Barrios CH, O’Shaughnessy J, et al. Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY- Breast06 (DB-06). Journal of Clinical Oncology [Internet]. 2024 Jun 10 [cited 2025 Jul 25];42(17_ suppl):LBA1000–LBA1000. Available from:
https://ascopubs.org/doi/pdf/10.1200/ JCO.2024.42.17_suppl.LBA1000
11. Wolff AC, Elizabeth Hale Hammond M, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/ college of American pathologists clinical practice guideline focused update. Journal of Clinical Oncology [Internet]. 2018 Jul 10 [cited 2025 Jul 25];36(20):2105–22. Available from:
https://ascopubs.org/doi/ pdf/10.1200/JCO.2018.77.8738
12. Baez-Navarro X, van Bockstal MR, Nawawi D, Broeckx G, Colpaert C, Doebar SC, et al. Interobserver Variation in the Assessment of Immunohistochemistry Expression Levels in HER2-Negative Breast Cancer: Can We Improve the Identification of Low Levels of HER2 Expression by Adjusting the Criteria? An International Interobserver Study. Modern Pathology. 2023 Jan 1;36(1).
13. Robbins CJ, Fernandez AI, Han G, Wong S, Harigopal M, Podoll M, et al. Multi- institutional Assessment of Pathologist Scoring HER2 Immunohistochemistry. Modern Pathology. 2023 Jan 1;36(1).
14. Fernandez AI, Liu M, Bellizzi A, Brock J, Fadare O, Hanley K, et al. Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue. JAMA Oncol. 2022 Apr 1;8(4):1–4.
15. Varga Z, Lebeau A, Bu H, Hartmann A, Penault-Llorca F, Guerini-Rocco E, et al. An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper. Breast Cancer Research. 2017 Dec 11;19(1):55.
16. Caselli E, Pelliccia C, Teti V, Bellezza G, Mandarano M, Ferri I, et al. Looking for
more reliable biomarkers in breast cancer: Comparison between routine methods and RT-qPCR. PLoS One. 2021 Sep 23;16(9):e0255580. 17. National Institute for Health and Care
About the author
Vinicio Tassani has been the Scientific Advisor at Cerca Biotech since 2021, and has over 25 years of international experience across clinical and commercial roles. A biomarkers specialist, he led clinical support and marketing for ACS, heart failure and stroke POC tests at Biosite (later Inverness/Alere/Abbott). He also contributed to the introduction of BNP as a routine biomarker in Eurpoe, supported the rollout of ST2 with Critical Diagnostics, and led the EMEA launch of
Excellence.
https://www.nice.org.uk/advice/ mib135/chapter/The-technology. 2018. MammaTyper in vitro diagnostic test for determining breast cancer subtypes.
EndoPredict at Myriad Genetics, deepening his expertise in breast cancer biomarkers.
Adaptable. Seamlessly adjusts to any
surgeon in any surgical environment.
Versatile. One system, built for
multiple specialities.
Digitally Driven. Empowering informed clinical
decisions through data and insights.
hello.uki@
cmrsurgical.com Find out more or contact us
MADE IN BRITAIN
Disclaimer: Versius Plus is part of a Versius ecosystem comprised of the Versius Surgical System, the EIZO CuratOR product, the vLimeLite visualisation system, the Versius Ultrasonic Dissector, and a suite of electrosurgical and non-electrosurgical instruments. vLimeLite and Versius are trade marks or registered trade marks of CMR Surgical in the UK and other countries. EIZO, the EIZO logo, and CuratOR are trade marks or registered trade marks of EIZO Corporation in Japan and other countries. Disclaimer: The Versius Plus offering and the product associated with are not launched globally. Availability in your region can vary. Please check availability of the product in your country with your local representative or your local customer service. The Versius Plus offering is not approved for sale in the U.S.
November 2025 I
www.clinicalservicesjournal.com 49
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64
